Candel Therapeutics is shifting from a risky clinical-stage biotech to a late-stage oncology company, driven by its lead asset CAN-2409 which showed positive Phase III results in localized prostate cancer. Additional promising data in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) support the company's 'pipeline in a product' strategy. The company's valuation seems too pessimistic considering upcoming regulatory milestones, a strong financial position extending to early 2028, and multiple clinical assets. Near-term catalysts include the prostate cancer Biologics License Application (BLA) submission, ongoing Phase III AURORA NSCLC trial, and emerging glioma data, with execution risk now more significant than clinical risk.
The JPMorgan BetaBuilders US Equity ETF (BBUS) received a hold rating amid volatile macroeconomic conditions and high valuations, especially in tech and communication sectors which make up a large part of its portfolio. Despite its low expense ratio ...
Bitcoin faces pressure even as the U.S. Dollar Index weakens and rate hike bets fade, due to record outflows from spot Bitcoin ETFs totaling $4.0 to $4.5 billion in June. A softer dollar typically supports Bitcoin by improving global purchasing power...
Imugene Ltd announced a second complete response in its Phase 1b azer-cel trial targeting patients with mantle cell lymphoma (MCL) who had failed prior BTKi therapy. The patient showed complete tumor shrinkage by Day 28, earlier than expected, highli...
Revolut will remove Tether's USDT stablecoin from its platform by August 31, 2026, disabling purchases from July 6. This move aligns with regulatory and risk considerations under the EU's new Markets in Crypto-Assets (MiCA) rules, which have led othe...
XRP price has rebounded to around $1.145, showing a 4% gain in 24 hours, after forming a double bottom near $1.05 and $1.0092, which suggests sellers may be losing control. The key level to watch is the $1.28 to $1.29 neckline; a daily close above th...
